• 1
    Glaxo-Wellcome, Lamictal Advisory Board Briefing Document, October 23, 1997.
  • 2
    Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691713.
  • 3
    Binnie CD. Van Emde Boas W, Kastelijn-Nolste-Trnite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:24854.
  • 4
    Eriksson A-S, Hoppu K, NergDrdh A, Boreus L. Pharmacokinetics of lamotrigine in children with intractable epilepsy [Abstract]. J Epilepsy 1994;7:326.
  • 5
    Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:35663.
  • 6
    Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191200.
  • 7
    Chapman AA, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:31559.
  • 8
    Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:5113.
  • 9
    Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:9917.
  • 10
    Binnie CD. The efficacy of lamotrigine. Rev Contemp Pharmacother 1994;5:11522.
  • 11
    Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in partial seizures: U.S. Lamotrigine Protocol 05 Clinical Trial Group. Neurology 1993;43:228491.
  • 12
    Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:11321.
  • 13
    Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997;337:180712.
  • 14
    Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:31222.
  • 15
    Brodie MJ, Richens A, Yuen AWC. for the Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:4769.
  • 16
    Perucca E. Add-on trial of lamotrigine followed by withdrawal of concomitant medication and stabilization on monotherapy. In: LoiseauP, ed. Lamotrigine: a brighter future. International Congress and Symposium Series 214. London : Royal Society of Medicine Press, 1996:2330.
  • 17
    Steiner TJ, Siveira C, Yuen AWC, and The North Thames Lamictal Study Group. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [Abstract]. Epilepsia 1994;35(suppl 7):61.
  • 18
    Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate Epilepsy Res 1997;26:42332.
  • 19
    Chang G. Lamictal (lamotrigine) monotherapy is a safe and effective treatment for partial seizures. Epilepsia 1997;38(suppl 3):S32.
  • 20
    Schachter S, Leppik I, Matsuo F, et al. for the US Lamotrigine Protocol 16 Clinical Study Group. A multicenter, placebo-controlled evaluation of the safety of lamotrigine (Lamictal) as add-on therapy in outpatients with partial seizures [Abstract]. Epilepsia 1992;33(suppl 3):119.
  • 21
    Foletti G, Schmidt M, Delisle MC, Molleyres D, Volanschi D. An open study on effectiveness of lamotrigine in the treatment of secondary bilateral synchrony, unsatisfactorily controlled by conventional drugs [Abstract]. J Neurol 1992;239(suppl 2):S71.
  • 22
    Oller LFV, Russi A, Oller Daurella L. Lamotrigine in the Lennox-Gastaut syndrome [Abstract]. Epilepsia 1991;32(suppl 1):58.
  • 23
    Uvebrant P, Bauzien PR. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:2849.
  • 24
    Richens A. Safety of lamotrigine. Epilepsia 1994;35(suppl 5):S3740.
  • 25
    Besag FMC, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal7) in paediatric patients with epilepsy. Seizure 1997;6:516.
  • 26
    Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine-induced rash in children. Neurology 1996;46:2402.
  • 27
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:127285.
  • 28
    Besag FMC. Reintroduction of lamotrigine after rash with initial exposure. Epilepsia 1997;38(suppl 8):S102.
  • 29
    Tavernor SJ, Wong ICK, Newton R, Brown SW. Rechallenge with lamotrigine after initial rash. Seizure 1995;4:6771.
  • 30
    Manasco P, Mullens L, Matsuo F. Skin rash associated with Lamictal: incidence, time to onset and risk factors. Epilepsia 1996;37(suppl 5):S164.
  • 31
    Brodie M. Lamotrigine monotherapy: an overview. In: LoiseauP, ed. Lamotrigine a brighter future. International Congress and Symposium Series 214. London : Royal Society of Medicine Press, 1996:439.
  • 32
    Wolkenstein P, Revuz J. Drug-induced severe skin reactions: incidence, management and prevention. Drug Safety 1995;13:5668.
  • 33
    Chaffin JJ, Davis SM. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997;31:7203.
  • 34
    Fogh K, Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997;6:635.
  • 35
    Sachs B, Ronnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced SJS: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997;195:604.
  • 36
    Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995;33:5957.
  • 37
    Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996;37:20812.
  • 38
    Wadelius M, Karlsson T, Wadelius C, Rane A. Lamotrigine and toxic epidermal necrolysis. Lancet 1996;348:1041.
  • 39
    Mackay FJ, Wilton LV, Pearce SN, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997;38:8816.
  • 40
    Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:16007.
  • 41
    Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a recorded linkage study. Neurology 1997;49:5426.
  • 42
    Konishi T, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993;152:6058.
  • 43
    King JA, Knight JE. Low incidence of rash associated with slow titration of lamotrigine. Epilepsia 1997;38(suppl 3):S32.
  • 44
    Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998;18:28196.